Drug Profile

RC 58

Alternative Names: RC-58

Latest Information Update: 28 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Yantai Rongchang Pharmaceutical
Developer RemeGen
Class Antineoplastics; Drug conjugates; Immunotoxins
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported B-cell lymphoma

Most Recent Events

28 Aug 2022 No recent reports of development identified for preclinical development in B-cell lymphoma in China (Parenteral)
23 Jul 2018 Preclinical trials in B-cell lymphoma in China (Parenteral) before July 2018
23 Jul 2018 Pharmacodynamics data from a preclinical trial in B-cell lymphoma released by RemeGen

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com